This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Current Discounted Rates End In:

  • 00
  • 00
  • 00
  • 00
Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Justin Murray, PhD
Principal Scientist, Hybrid Modality Engineering at Amgen, Inc.


Justin received his BSc in Chemistry from the Colorado School of Mines. He received his PhD from the University of Wisconsin - Madison under the direction of Prof. Sam Gellman for research on beta-peptide inhibitors of protein-protein interactions. He joined the Peptide Research & Discovery group at Amgen in 2006 and focused his research on disulfide-rich peptide inhibitors of ion channels and developed his interests in high-throughput synthesis, laboratory automation, and conjugation technologies. Now in the Selection & Modality Engineering group, Justin is working to establish oligonucleotide therapeutics as a new modality for Amgen.

Agenda Sessions

  • Identification and Optimization of a Minor Allele-specific siRNA to Prevent PNPLA3 I148M-driven Nonalcoholic Fatty Liver Disease